Launching recombinant procollagen type I N-propetide antigen: Advancing Bone Disease Awareness


In light of the growing elderly population worldwide, there is an escalating focus on bone metabolism-related diseases. Procollagen type I N-propetide (PINP) in blood is recommended as a reference marker for bone formation in osteoporosis by the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry (IFCC) bone marker standards joint working group. The IOF-IFCC have underscored the importance of the biomarker in diagnosing bone diseases like Paget’s disease, rickets, osteomalacia, and osteoporosis.

Bone turnover biomarkers (BTMs) provide critical clinical tools for assessing and monitoring bone metabolism, offering quicker and more direct measure of intervention results compared to standard bone density measurements. Among these, PINP, in particular, has emerged as a recommended reference marker for bone formation in osteoporosis, aiding in monitoring antiresorptive and anabolic therapies. Its effectiveness in tracking Paget’s disease activity also underscores its clinical significance.

As we launch recombinant A1-PINP antigen (Cat# 8PIN7), we aim to highlight its critical role in modern healthcare and promote its wider acceptance in clinical practice. Hytest’s recombinant A1-PINP antigen can be used as a standard or calibrator in the development of PINP immunoassays. Studies shown that the performance of the recombinant A1-PINP antigen closely matches that of native PINP in the gel-filtration studies with human serum. For more detailed information, please refer to the product material or contact our Sales Team.

More information:

Product page: A1-PINP-Human-Recombinant
PDF DataSheet: A1 PINP DataSheet

Do you need samples?

We are happy to make you an offer